Organon & Co. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Group 1: Allegations and Impact - The allegations state that Organon provided overly positive statements to investors while concealing adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a significant decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation for participation [4]. Group 3: Law Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [5].